Final analysis of the GMALL-PH-01 trial: phase II study of standard chemotherapy in combination with dasatinib in first line treatment of Philadelphia chromosome positive acute lymphoblastic leukemia
Open Access
- 8 February 2025
- journal article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 66 (6) , 1079-1087
Abstract
Imatinib (IMA) plus chemotherapy followed by allogeneic hematopoietic cell transplantation (HCT) is established treatment for Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). We investigated the use of dasatinib (DASA) combined with intensive chemotherapy in ALL (18-55 years) first-line in a prospective, multicenter phase II trial by the GMALL study group. 140 mg DASA QD was used with a pediatric-based induction and consolidation chemotherapy according to GMALL 07/2003 protocol with recommended consecutive HCT. Nineteen of 20 planned patients were enrolled in 12 centers. The hematologic CR rate after induction was 79% with an overall MRD negativity rate of 62.5%. Six patients died during induction and two discontinued therapy. This regimen achieved deep molecular responses but was associated with a higher than expected early mortality (21%) and was stopped prematurely due to toxicities. The GMALL therefore adopted a combination of low intensity chemotherapy plus IMA as its current induction regimen.Keywords
This publication has 12 references indexed in Scilit:
- Management of ALL in adults: 2024 ELN recommendations from a European expert panelBlood, 2024
- Philadelphia Chromosome–Positive Acute Lymphoblastic LeukemiaNew England Journal of Medicine, 2022
- Dasatinib–Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in AdultsNew England Journal of Medicine, 2020
- Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome–positive ALLBlood, 2016
- Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 studyThe Lancet Oncology, 2015
- Phase II trial of HyperCVAD and Dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemiaAmerican Journal of Hematology, 2013
- First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemiaBlood, 2010
- Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008Leukemia, 2009
- Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapyCancer, 2009
- Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)Blood, 2007